Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Leading nanomedicine firm Nanobiotix successfully closes its $ 11 million series-C financing round

Abstract:
Nanobiotix, based in Paris, France, announces the closing of a $ 11 million series-C financing round. The company develops innovative therapeutic products for cancer using nanotechnologies.

Leading nanomedicine firm Nanobiotix successfully closes its $ 11 million series-C financing round

Paris | Posted on May 3rd, 2010

Nanobiotix raised US 11 million from a strong new and existing syndicate of investors. CIC Vizille Capital Innovation has led this new round with Masseran Gestion. Existing shareholder have strongly participated in the round, Matignon Technologies, OTC Asset Management, Cap Decisif Management, and Amorçage Rhône-Alpes.

"This successful closing is the recognition of the value of Nanobiotix breakthrough technology NanoXray. This financing will enable us to continue to advance our lead programs through clinical studies. We first plan on reinforcing our scientific /developpement team and resources: we are entering our first-in-man clinical study of nanoXray therapeutics with IGR Institut Gustave Roussy, - a Europe leading cancer treatment center - for Soft Tissue Sarcoma as initial indication. First preclinical data are very promising: safety in animals of NBTXR3 - when activated by ionizing radiation has been demonstrated; performance has clearly shown the potential of this product to become a new approach for cancer treatment," says Dr Laurent Levy, PhD, co-founder and CEO of Nanobiotix, a worldwide pioneer in nanomedicine.

"We are thrilled to be part of this very exciting adventure and pleased to help accelerate the development of a new class of cancer treatment, more effective and less deadly to healthy tissues. Nanobiotix has mastered the critical issues related to NanoXray reproductibility, scalability and stability," says Karine Lignel; CIC - Vizille Capital Innovation.

Since its creation in 2003, the company has made tremendous progresses and obtained significant results. It has a well balanced pipeline and a unique nanomedicine expertise in developing a very promising therapy for cancer treatment.

"We are confident in the development of Nanobiotix and its technology. We truly believe that is the best risk reward products in biotech field," says Jerome Snollaerts; Cap Decisif Management.

In parallel to the ongoing clinical developments, Nanobiotix has built an industrial and academic collaborative projects portfolio including research programs and industrial partnering, like Sonodrug with Philips Research or Biotech Corp in Malaysia.

"This is a significant step to the development of nanoXRay and we are excited to be that close to offer a potential alternative to patients," Patrick Langlois; Chairman of the non executive board.

####

About Nanobiotix
Nanobiotix is a leading nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop "nanoXray a technology platform that is expected to be turned 'on' and 'off' outside the body to selectively treat a variety of cancers safely and noninvasively. Use of nanoXray is intended to resolve radiation therapy's biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of Xray is necessary. After nanoXray nanoparticles accumulate in the target tissues, a standard X-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells. This mechanism suggests total control of the intended therapeutic effect.

About NanoXray Platform
NanoXray therapeutic platform is designed to enable the precise destruction of cancer cells made possible by the controlled application of an outside the body energy source, in that case an X-ray. The nanoparticles that comprise the nanoXray platform allow for an extensive combination of therapeutic modalities and malignant pathologies. Nbtxr3, the first product to be developed from the nanoXray pipeline, also is the first-in-class product to be activated by radiotherapy. The intended initial indications for Nbtxr3 are:

Soft Tissue Sarcoma - Hepatic Cancer - Colon cancer - Lung cancer - Pancreatic cancer

Dr Laurent Levy will be attending BIO Chicago, from May 3 to May 6.

For more information, please click here

Contacts:
60 rue de Wattignies
Bat B 3rd floor
75012 Paris, France

Tel : + 33 (0) 1 40 26 04 70
Fax : +33 (0) 1 40 26 04 44

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Possible Futures

Application of air-sensitive semiconductors in nanoelectronics: 2-D semiconductor gallium selenide in encapsulated nanoelectronic devices September 22nd, 2017

Researchers set time limit for ultrafast perovskite solar cells September 22nd, 2017

DNA triggers shape-shifting in hydrogels, opening a new way to make 'soft robots' September 21st, 2017

Physicists develop new recipes for design of fast single-photon gun Physicists develop high-speed single-photon sources for quantum computers of the future September 21st, 2017

Investments/IPO's/Splits

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Nanometrics Announces Upcoming Investor Events August 3rd, 2017

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Nanomedicine

Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Graphene based terahertz absorbers: Printable graphene inks enable ultrafast lasers in the terahertz range September 13th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017

Announcements

Quantum twisted Loong confirms the physical reality of wavefunctions September 23rd, 2017

Application of air-sensitive semiconductors in nanoelectronics: 2-D semiconductor gallium selenide in encapsulated nanoelectronic devices September 22nd, 2017

Researchers set time limit for ultrafast perovskite solar cells September 22nd, 2017

DNA triggers shape-shifting in hydrogels, opening a new way to make 'soft robots' September 21st, 2017

Nanobiotechnology

DNA triggers shape-shifting in hydrogels, opening a new way to make 'soft robots' September 21st, 2017

Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017

Magnetic cellular 'Legos' for the regenerative medicine of the future September 12th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project